The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $377.73

Today's change+17.09 +4.74%
Updated May 5 4:00 PM EDT. Delayed by at least 15 minutes.
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $377.73

Today's change+17.09 +4.74%
Updated May 5 4:00 PM EDT. Delayed by at least 15 minutes.

Regeneron Pharmaceuticals Inc up sharply

Regeneron Pharmaceuticals Inc closed up sharply Thursday, rallying (U.S.)$17.09 or 4.74% to (U.S.)$377.73. Over the last five days, shares have lost 3.47% and are down 30.42% for the last year to date. This security has underperformed the S&P 500 by 17.00% during the last year.

Key company metrics

  • Open(U.S.) $377.13
  • Previous close(U.S.) $360.64
  • High(U.S.) $381.61
  • Low(U.S.) $369.11
  • Bid / Ask(U.S.) $369.00 / (U.S.) $384.00
  • YTD % change-30.42%
  • Volume1,500,735
  • Average volume (10-day)765,060
  • Average volume (1-month)926,629
  • Average volume (3-month)960,872
  • 52-week range(U.S.) $348.96 to (U.S.) $605.93
  • Beta1.08
  • Trailing P/E68.56×
  • P/E 1 year forward31.45×
  • Forward PEG1.52×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $5.51
Updated May 5 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue1,0981,137999870
Total other revenue--------
Total revenue1,0981,137999870
Gross profit9871,028910786
Total cost of revenue1111098984
Total operating expense869745670587
Selling / general / administrative295210175159
Research & development461426390343
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)20161
Other operating expenses, total--------
Operating income229392329283
Interest income (expense), net non-operating-4-2-3-6
Gain (loss) on sale of assets--------
Other--------
Income before tax227393328277
Income after tax15521019576
Income tax, total72183133201
Net income15521019576
Total adjustments to net income--------
Net income before extra. items15521019576
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items15521019576
Inc. avail. to common incl. extra. items15521019576
Diluted net income15521019576
Dilution adjustment0------
Diluted weighted average shares115116115115
Diluted EPS excluding extraordinary itemsvalue per share1.341.811.690.66
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share1.351.811.770.67